seasonal trivalent influenza VLP vaccine

The **seasonal trivalent influenza VLP vaccine** is a virus-like particle (VLP)-based vaccine designed to protect against seasonal influenza by mimicking the structure of influenza viruses without containing live or replication-competent virus. It targets three strains—two influenza A subtypes (H1N1pdm09 and H3N2) and one B/Victoria lineage strain—selected annually based on global surveillance data, with specific recommendations for recombinant-based formulations like A/Wisconsin/67/2022 (H1N1)pdm09-like, A/Massachusetts/18/2022 (H3N2)-like (2024-2025), or similar for subsequent seasons[1][2][3][6]. Developed using recombinant technology, VLPs display viral hemagglutinin on self-assembling particles produced in insect cells, eliciting strong humoral and cellular immune responses without the egg-adaptation issues of traditional vaccines; it is primarily indicated for prevention of seasonal influenza in adults 18 years and older, with developers including Novavax (e.g., their NanoFlu program).[1][2][3]

Other names

trivalent influenza vaccine